

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_83309
Title of the Manuscript:	BISPHOSPHONATE INDUCED OSTEONECROSIS OF THE JAW IN RENAL SARCINODOSIS – A CASE REPORT
Type of the Article	Case study

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljpri.com/index.php/JPRI/editorial-policy>)

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	<p>BISPHOSPHONATES INDUCED OSTEONECROSIS OF THE JAW IN RENAL SARCOIDOSIS-A CASE REPORT</p> <p>This is an interesting, though not uncommon, side effect of bisphosphonates. The paper is written in a very confusing way and would need some adjustments for better understanding</p> <p>Introduction</p> <p>The following sentence needs to be rewritten: The intravenously administered bisphosphonates show highest prevalence of BIOJN it is about</p> <p>In the introduction, it would be interesting to point out whether any of these drugs would have a higher or lower prevalence in BIONJ</p> <p>Case report</p> <p>The following phrase: To regulate sérum calcium level.....should be rewritten, because it is difficult to understand.</p> <p>Laboratory values were missing in the case, especially in relation to total calcium, ionized calcium, blood count, urea, creatinine, etc.</p> <p>Discussion</p> <p>At the end of the discussion, stages (?) of BIONJ were placed, and then treatment? Are they tables? Are they placed in the discussion? Does zoledronic acid cause this injury more often than other bisphosphonates?</p>	<p>The changes have been incorporated in the introduction</p> <p>Yes it is done</p> <p>These values of the patient was done by the Nephrologist at the time of diagnosis 7 years back.</p> <p>-Yes as suggested it is added in the discussion. -1 table is present -Yes zoledronic acid predisposes to BIONJ than other Bisphosphonates</p>
<u>Minor</u> REVISION comments	Written English needs to be improved	Sure
<u>Optional/General</u> comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	NO